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What is already known about this subject
￿ Cholesterol is known to be essential for fetal
development.
￿ Statins, which inhibit cholesterol production, have
therefore been considered as potential teratogens and are
contraindicated in pregnancy.
￿ Data available thus far on the risks of congenital
anomalies associated with statin therapy have come from
non-analytic postmarketing surveillance studies.
￿ Given the increasing use of statins in women of
childbearing age, there is a need for a population-based
study on the risks of congenital anomalies associated with
gestational statin use.
What this study adds
￿ In this pharmacoepidemiological study, we determined the
risk of congenital anomalies in women who filled
prescriptions for statins during the first trimester of pregnancy,
compared with women who had stopped statins before
pregnancy or those who used fibrates during pregnancy.
￿ We found no evidence of an increased risk of fetal anomalies
among first-trimester statin users, or any discernable pattern
of congenital anomalies among live births.
￿ However, in the absence of outcome data on nonlive births,
conclusions remain uncertain.
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Aims
Evidence from animal studies suggests that statin medications should not be taken
during pregnancy. Our aim was to examine the association between the use of statins
in early pregnancy and the incidence of congenital anomalies.
Methods
A population-based pregnancy registry was built. Three study groups were assembled:
women prescribed statins in the first trimester (group A), fibrate/nicotinic acid in the
first trimester (group B) and statins between 1 year and 1 month before conception,
but not during pregnancy (group C). Among live-born infants, we selected as cases
infants with any congenital anomaly diagnosed in the first year of life. Controls were
defined as infants with no congenital anomalies. The rate of congenital anomalies in
the respective groups was calculated. Adjusted odds ratios (OR) and 95% confidence
intervals (CI) were also calculated.
Results
Our study group consisted of 288 pregnant women. Among women with a live birth,
the rate of congenital anomalies was 3/64 (4.69%; 95% CI 1.00, 13.69) in group A,
3/14 in group B (21.43%; 95% CI 4.41, 62.57) and 7/67 in group C (10.45%; 95%
CI 4.19, 21.53). The adjusted OR for congenital anomalies in group A compared with
group C was 0.36 (95% CI 0.06, 2.18).
Conclusion
We did not detect a pattern in fetal congenital anomalies or evidence of an increased
risk in the live-born infants of women filling prescriptions for statins in the first
trimester of pregnancy. Conclusions, however, remain uncertain in the absence of data
from nonlive births.
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution2.5, which does not permit commercial exploitation.
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High blood cholesterol has been shown to be a risk
factor for coronary heart disease (CHD) and cardiovas-
cular death [1]. The rise in obesity, physical inactivity,
cigarette smoking, high-carbohydrate diets [2, 3] and
Type 2 diabetes [4] may be implicated in the increasing
numbers of young people who are now considered for
treatment with antilipaemic drugs. Furthermore, a strong
genetic component to elevated cholesterol has also been
identiﬁed, prompting the early screening of young adults
who may be at risk [5]. Heterozygous familial hyper-
cholesterolaemia (HeFH) affects as many as 1 in 500
people with high prevalence in certain subpopulations
such as people of Quebecois extraction. The incidence
of HeFH in Quebec is about 2.5-fold higher than in the
rest of Canada [5].
Pregnant women or those likely to become pregnant
clearly fall within the populations that might become
targets for antilipaemic drug therapy. During normal
pregnancy, there is a steady physiological increase in
serum lipid concentrations, so that by the third trimester
triglyceride levels are 300–400% higher and cholesterol
levels 25–90% higher than in the nonpregnant state [6].
Nevertheless, the recommendation is for lipid-lowering
agents (especially statins) to be discontinued before con-
ception, or even during the 5–10 years while women
have children because of the uncertainty over their
safety for the fetus [3, 6]. This contraindication is not
always respected and cases may arise where women are
exposed to a statin during pregnancy, either by intent
or inadvertently; indeed, 50% of pregnancies are
unplanned [7] and many women may not be aware of
their status until well into the critical weeks of organ-
ogenesis, by which time inadvertent exposure may
already have occurred. Discontinuation of lipid-
lowering medications for the relatively short duration of
pregnancy is thought to have little impact on long-term
therapy for primary hypercholesterolaemia [6] and is
unlikely to affect outcomes of CHD. One exception
may be in homozygous familial hypercholesterolaemia,
where a case report has suggested an association
between markedly elevated maternal serum cholesterol
and fetal intrauterine growth restriction [8]. However,
there is no evidence that given close obstetrical care,
satisfactory outcomes for both mother and baby cannot
be achieved [8–10].
No controlled studies have assessed the teratogenic
potential of any statins in humans. However, case-series
and postmarketing surveillance data are available.
A recent notable report was on a case series [11] (corri-
gendum [12]) of all Food and Drug Administration
(FDA) reports, literature and manufacturer data on statin
exposures during pregnancy. Of 214 ascertained preg-
nancy exposures, of which 70 had evaluable outcomes,
there were 22 cases of newborns with structural defects,
18 of which resulted in live births. A further analysis
[13], which considered prospective reports of maternal
exposure to simvastatin and lovastatin, was able to cal-
culate the incidence rate of congenital anomalies.
Among their reported live births, the incidence rate of
congenital anomalies was 5/154 (3.2%).
Reports available to date have been based on volun-
tary submissions or from postmarketing surveillance
monitoring; such studies are limited by their lack of
appropriate comparator groups and under-reporting, and
also usually lack denominator data, such as user popu-
lation and drug exposure patterns, that would provide
the exact number of patients exposed to the medicine
and thus at risk of the adverse event [14]. Therefore, we
undertook a study to examine the risk of congenital
anomalies associated with gestational exposure to statins
or other antilipaemic medications in a deﬁned popula-
tion of women in Quebec, Canada. Our objective was to
study the relationship between three maternal exposure
groups to antilipaemic medications, representing the
most likely pattern of antilipaemic medication use in
relation to pregnancy, and the outcome of any congenital
anomalies in their live-born infants; these three groups
consisted of those who stop statins before pregnancy,
those who continue, and those who use nonstatin anti-
lipaemic medications during the gestational period.
Methods
Data sources
We used three administrative databases of the Province
of Quebec: the Régie de l’Assurance Maladie du Québec
(RAMQ), Med-Echo, and the ﬁchier des événements
démographiques du Québec (birth and death registries)
of l’Institut de la Statistique du Québec (ISQ) (Figure 1).
The RAMQ database contains information on medical
services (diagnoses and procedures) received by all
Quebec residents.All diagnoses are classiﬁed according
to the International Classiﬁcation of Diseases, 9th revi-
sion (ICD-9). The RAMQ covers all Quebec residents
for the cost of physician visits, hospitalizations and pro-
cedures, but covers only a proportion of residents for the
cost of prescribed medications. The RAMQ drug plan
covers individuals 65 years old, recipients of social
assistance (welfare beneﬁciaries) and workers and their
families (adherents) who do not have access to a private
insurance programme, accounting for approximately
43% of the overall Quebec population [15]. It is also
estimated that 30% of women between 15 and 45 years
of age in Quebec are covered by the RAMQ drug plan
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vincial database which records hospitalization data for
all Quebec residents; it also records gestational age for
planned abortions, miscarriages and deliveries. The
ﬁchier des événements démographiques du Québec
(ISQ) provides demographic variables on the mother,
father and baby as well as birth weight and gestational
age for live births and stillbirths. Linkage between the
databases was achieved as illustrated in Figure 1. The
RAMQ, Med-Echo and ISQ databases have previously
been used for epidemiological research [16–19]. Data
recorded in the medication database of the RAMQ have
been evaluated and found to be comprehensive and valid
[20]. The same has been found for medical diagnoses
recorded in the Med-Echo database [21].
Population
The RAMQ, Med-Echo and ISQ databases were linked
together to create the ‘Medication and Pregnancy’ reg-
istry, which contains data on all pregnancies that
occurred in Quebec between 1 January 1997 and 30
June 2003. This population-based pregnancy registry is
composed of women with a diagnosis or procedure code
related to pregnancy identiﬁed from data in the RAMQ
or Med-Echo databases.
Within the ‘Medication and Pregnancy’ registry,
women meeting the following eligibility criteria were
included in the present study: they had to (i) be between
15 and 45 years of age at the date of entry in the registry
deﬁned as the ﬁrst day of gestation, (ii) be continuously
insured by the RAMQ drug plan for at least 12 months
before the ﬁrst day of gestation, and during their preg-
nancy, and (iii) have ﬁlled a prescription for a statin or
ﬁbrate or nicotinic acid in the year before or during
pregnancy. If a woman had more than one pregnancy
between 1997 and 2003, the ﬁrst pregnancy meeting
eligibility criteria was included.
Definition of study groups
Within the study population, all women who had ﬁlled a
prescription for a statin, a ﬁbrate or nicotinic acid at any
time from 1 year before the date of entry in the registry
until the end of pregnancy were selected. The drugs
considered were those reimbursed by the RAMQ at the
time of the study, and included the following statins:
atorvastatin, ﬂuvastatin, lovastatin, pravastatin, rosuvas-
tatin and simvastatin. The ﬁbrates considered included
fenoﬁbrate, bezaﬁbrate and gemﬁbrozil. In addition to
these drugs, nicotinic acid was also considered.
Women were excluded if they had also ﬁlled a pre-
scription for a category X drug, deﬁned as a medication
where studies in animals or humans have demonstrated
fetal abnormalities or where there is evidence of fetal
risk based on human experience or both, and the risk
of the use of the drug in pregnant women clearly out-
weighs any possible beneﬁt [22]. The category X drug
group included: carbamazepine, phenytoin, valproic
acid, lithium, acitretin, isotretinoin, antineoplastic
agents (American Hospital Formulary System class
10 : 00.00), leﬂunomide and androgens (including
danazol, testosterone and methyltestosterone).
Those pregnancies resulting in a live birth were
selected for our analysis and were identiﬁed by search-
ing the RAMQ/Med-Echo databases for ICD-9 codes
and procedure codes related to childbirth and normal
delivery, and by searching the ISQ database. For
Figure 1
Linkage between administrative databases
used in study. NAM, Numéro d’assurance
maladie (unique personal identification
number); ICD-9, International Classification
of diseases, 9th revision; ED, emergency
department; DoB, date of birth RAMQ
Medications dispensed
    Date, drug, form, duration,
    dose
Medical services and ED visits:
    Diagnostic codes (ICD-9)
    Procedure codes 
MedEcho
Hospitalisations:
    1st & 2nd diagnostic
    codes (ICD-9) 
ISQ
Mother: Demographic
data
Baby: DoB, gender,
birthweight, gestational
age 
Medication & Pregnancy
Registry
Linked by:
Baby’s name
Mother’s name
Family name
DoB of mother and baby
NAM
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as terminating in either a speciﬁed abortion (ICD-9
codes: 635.0–635.9, 636.0–636.9, 779.6, identiﬁed at
any time up to 60 days after the end of pregnancy, to
allow for delayed records) or other outcome, including
unspeciﬁed abortions, miscarriages and stillbirth.
We deﬁned three study groups of interest as follows.
Group A was deﬁned as women who had ﬁlled pre-
scriptions for statins only, before and during the ﬁrst
trimester of pregnancy, but who did not use ﬁbrates or
nicotinic acid; group B as women who had ﬁlled pre-
scriptions for ﬁbrates or nicotinic acid only, before and
during the ﬁrst trimester, but who did not use statins;
group C as women who had ﬁlled prescriptions for
statins only in the period between 1 year before con-
ception and 1 month before conception, and who did
not have any ﬁlled prescriptions for any antilipaemic
medication (statins, ﬁbrates or nicotinic acid) in the
period between 1 month before conception and the end
of pregnancy. These groups were purposefully selected
so that they all currently or previously had an indica-
tion for antilipaemic medication treatment and repre-
sented the treatment groups of clinical interest, those
who stop their statins before pregnancy, those who
continue their statins and those who use nonstatin anti-
lipaemic medications.
Covariates
Socio-demographic variables (from the RAMQ/ISQ
database) as determined at the end of pregnancy were
added, including maternal age (deﬁned as a continuous
variable and a categorical variable), marital status (living
alone vs. cohabiting), number of years of education
achieved as a continuous variable and categorically
deﬁned as: secondary education not completed
(<11 years); secondary education completed (11 years);
post secondary education (12–15 years); and univer-
sity education (16 years). RAMQ insurance status
(welfare beneﬁciary vs. adherent) and place of residence
(urban vs. rural) were also included. Healthcare utiliza-
tion variables (RAMQ/Med-Echo databases) were
selected as markers of health status; hospitalization and
emergency department (ED) visits (yes/no) and number
of prescribers 2 (yes/no) were determined for the year
before and during pregnancy; the number of medical
visits 3 (yes/no) was determined for the year before
pregnancy; a visit to an obstetrician or gynaecologist
(ob/gyn) (yes/no) was determined for the period during
the pregnancy. Prenatal visits, deﬁned as being 7o r
as a continuous variable, was also considered. Those
women who had had a pregnancy within the previous
year were also identiﬁed.
The presence/absence of the following chronic
co-morbidities were determined using the RAMQ/Med-
Echo databases: the diagnosis of hypothyroidism (ICD-9
244.0) or the ﬁlling of prescriptions for thyroid medica-
tions [American Hospital Formulary Service (AHFS)
68:36.04] at any time before or during pregnancy; the
diagnosis of diabetes in the year before pregnancy
(ICD-9 250.0–250.9, 271.4, 790.2) or gestational diabe-
tes diagnosed at 26 weeks of pregnancy (ICD-9 648.0,
648.8), or the ﬁlling of prescriptions for medications for
diabetes in the 12 months before and during pregnancy,
including insulins and oral hypoglycemics (AHFS
68 : 20.08, 68 : 20.20, 68 : 20.92); the diagnosis of
chronic hypertension in the year before and during preg-
nancy (deﬁned by the presence of ICD-9 codes 401.0–
405.9, 362.1, 416.0, 437.2, 796.2), or the ﬁlling of
prescriptions for any antihypertensive drugs (AHFS
class 24 : 08), or gestational hypertension deﬁned as a
diagnosis made at 20 weeks of pregnancy and identi-
ﬁed with ICD-9 codes 642.0–642.9. Both diabetes and
hypothyroidism are causes of secondary hyperlipi-
daemia [23] and, together with hypertension, represent
clinically important co-morbidities frequently found in
pregnant women.
We also considered the number of different medica-
tions prescribed (>2, yes/no) other than statins or
ﬁbrates/nicotinic acid during pregnancy. Where such
prescribed medications were considered, we took into
account those prescriptions ﬁlled before pregnancy but
whose duration overlapped into the period of pregnancy.
The data collected on the babies included birth weight
and gender (ISQ database). As there is an increased risk
of prematurity in fetuses with a congenital anomaly [24],
we also reported the percentage of premature births
(<37 weeks gestational age at birth).
Cases and controls
We investigated the presence of major and minor con-
genital anomalies in live-born babies. Cases were
deﬁned as infants born with any congenital anomaly.
These were identiﬁed by searching the RAMQ and Med-
Echo databases for ICD-9 codes 740.0–759.9 among
those women with live births. The index date for case
deﬁnition was considered as the end of pregnancy.
However, we also searched for records of congenital
anomalies made within the ﬁrst 12 months of each
infant’s life, to allow for delayed detections or registra-
tions and enhance the detection of anomalies. Controls
were deﬁned as infants with no (neither major nor
minor) congenital anomaly documented in the ﬁrst
12 months of life.
Statin use during pregnancy and birth defects
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Pregnancy outcomes in the three study groups are
described. Further descriptive statistics were performed
only for those women with live births. Descriptive
statistics were also used to describe the population by
case status. The congenital anomalies detected, stratiﬁed
by study group, are also listed.
The incidence of congenital anomalies for each study
group was calculated using the number of reported
anomalies in mother–baby-linked live births as the
numerator and the total number of mother–baby-linked
live births for each group as the denominator. Conﬁ-
dence intervals (CIs) were calculated using the method
of Haenszel et al. [25] for Poisson-distributed variables.
The independent effect of the study group status (using
group B as the reference group) and of maternal or
infant characteristics on congenital anomalies was esti-
mated by univariate logistic regression. These analyses
were repeated on a subset comparing group A with
group C (reference group). For each variable, crude
numbers for cases and controls are displayed. Two mul-
tivariate logistic regression models were performed to
control simultaneously for potential confounders. The
ﬁrst model included the entire study cohort stratiﬁed by
study group, using group B as the reference group. The
second model included groups A and C, using group C
as the reference group. Covariates for inclusion were
selected by the backward stepwise method with a sig-
niﬁcance criterion for removal from the model of
P > 0.25. Maternal age at end of pregnancy and the
following measures of socioeconomic status were
retained in the model: place of residence, insurance
status, marital status and years of education achieved.
To test for a curvilinear relationship between age and
congenital anomaly, a quadratic term (age squared) was
added to the linear term in a separate model. There
were missing data in two variables, marital status
(7.6%) and years of education achieved (8.3%). This
was dealt with by assuming cohabitation for marital
status and secondary education completed (11 years’
education), where data were missing. We examined the
effect on our model of reversing these assumptions and
adopting living alone as the default for marital status,
and for education assuming either secondary education
not completed (10 years) or university education
(16 years’ education).
Descriptive and statistical analyses were performed
using the SAS System for Windows V8.0 (SAS Institute
Inc., Cary, NC, USA). Ethics approval was obtained
from the Research Ethics Board of CHU Sainte-Justine
and from the Commission for access to information of
Quebec.
Results
The Medication and Pregnancy registry included
110 313 women. Of these, 153 women received a statin
during the ﬁrst trimester of pregnancy (group A), 29
received a ﬁbrate or nicotinic acid in the ﬁrst trimester of
pregnancy (group B) and 106 women received a statin
in the period between 1 year before conception and
1 month before conception (group C). The pregnancy
outcomes for these three groups are described in
Figure 2. The three most commonly ﬁlled prescriptions
for a statin among the women in group A and group C
were for atorvastatin, pravastatin and simvastatin. In all
cases of ﬁrst-trimester statin or ﬁbrate use, prescriptions
were not renewed in the second trimester.
We were able to perform a link of mother–baby data
for 64 of the 69 known live births for group A. In group
B mother–baby linkage was possible in 14 out of the 15
known live births, whereas in group C all mothers were
successfully linked to babies (67/67). Further results
refer to these groups.
The patterns of antilipaemic medications used are pre-
sented in Table 1. For groupA, the patterns of statin use
before pregnancy and during pregnancy were analysed
separately. Five women made treatment changes: three
in group A in the period before pregnancy and two in
group C. In three cases, a switch was made to atorvas-
tatin from pravastatin or ﬂuvastatin, in one case a switch
was made from simvastatin to atorvastatin then back to
simvastatin, and in one case from ﬂuvastatin to simvas-
tatin. In Table 2, the frequency of the most commonly
ﬁlled prescriptions in groupAis compared with those in
groups B and C.
The rate of congenital anomalies in groupAwas 3/64
(4.69%; 95% CI 1.00, 13.69) (Table 3). The rate in
group B was 3/14 (21.43%; 95% CI 4.41, 62.57) and in
group C, 7/67 (10.45%; 95% CI 4.19, 21.53). By com-
parison, the live-birth congenital anomaly rate in the rest
of our registry was 6.97% (95% CI 6.77, 7.17) [26].
Table 3 also shows variable information for the entire
study cohort according to case and control status. Crude
OR and 95% CI for the occurrence of any major or
minor congenital anomaly are shown as an indication of
the uncertainty around the estimation of risk. Similarly,
Table 4 displays data for groups A and C.
The ﬁrst multivariate analysis of the entire study
cohort, stratiﬁed by study group (using group B as the
reference group), included the variables; maternal age
at end of pregnancy (as a continuous variable), all the
socioeconomic variables as previously described, and
the following categorical indicators of co-morbid dis-
eases: diabetes, hypertension, hypothyroidism, comedi-
cations and medical visits before pregnancy and history
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Br J Clin Pharmacol 64:4 501of pregnancy in previous year. The adjusted OR for
congenital anomalies for group A was 0.79 (95%
CI 0.10, 6.02) and for group C 1.74 (95% CI 0.27,
11.27), when compared with group B. In the second
multivariate analysis, which included groups A and
C, using group C as the reference group, the ﬁnal
model was adjusted for age at end of pregnancy (as a
continuous variable), socioeconomic variables as previ-
ously described, and the following categorical indicators
of co-morbid diseases: diabetes, hypothyroidism, come-
dications, medical visits before pregnancy, low birth
weight and baby’s gender. The adjusted OR for group
Table 1
Antilipaemic medications prescribed according to study group in women with live births
Group A
Prescribed statins only before and
during first trimester, n = 64*
Group B
Fibrates or nicotinic acid
only prescribed before
and during first trimester,
n = 14*
Group C
Statins only, prescribed
between 1 year before
and 1 month before
pregnancy n = 67*†
Statins prescribed
before pregnancy
Statins prescribed
during pregnancy
Cholesterol medication
Atorvastatin, no. (%) 32 (53.33) 33 (60.00) 36 (52.17)
Fluvastatin, no. (%) 3 (5.00)‡ 2 (3.64) 4 (5.80)¶
Lovastatin, no. (%) 2 (3.33) 2 (3.64) 1 (1.45)
Pravastatin, no. (%) 12 (20.00)§ 11 (20.00) 15 (21.74)††
Simvastatin, no. (%) 11 (18.33)** 7 (12.73) 13 (18.84)
Bezafibrate, no. (%) 1 (7.14)
Fenofibrate, no. (%) 12 (85.71)
Gemfibrozil, no. (%) 1 (7.14)
*Women with live births and complete mother–baby linkage data. Numbers of women are fewer than in Figure 1 , as there were
a few women with incomplete linkage of data with their babies. †Includes one woman with a twin birth. ‡One woman used
fluvastatin and changed to simvastatin. §One woman used pravastatin, then changed to atorvastatin. ¶One woman used
fluvastatin, then changed to atorvastatin. **One woman used simvastatin, then changed to atorvastatin, then back to simvastatin.
††One woman used pravastatin, then changed to atorvastatin.
Table 2
Comparison of commonly prescribed medications between group A and groups B and C
Group A
Prescribed statins
only before and
during first
trimester, n = 64
Group B
Fibrates or nicotinic
acid only prescribed
before and during
first trimester, n = 14
Group C
Statins only, prescribed
between 1 year before
and 1 month before
pregnancy, n = 67
Antiemetics (%) 8.22 4.82 6.38
Blood glucose reagents (%) 7.31 8.43 6.91
Penicillins (%) 6.85 4.82 6.38
Antihypertensive medication (%) 4.57 3.61 2.13
Insulin (%) 4.11 7.23 3.72
Antifungals (%) 4.11 4.82 5.85
Nonsteroidal anti-inflammatory drugs (%) 3.65 1.2 7.45
Antidepressants (%) 3.65 2.41 2.13
Thyroid hormones (%) 3.65 1.20 1.60
Quinidine (%) 3.20 – 1.06
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Risk of any congenital anomaly in relation to study group and characteristics
Cases,
n (%)
Controls,
n (%) Crude OR 95% CI P-value
Study group
Group B fibrates or nicotinic acid only prescribed before
and during first trimester, n = 14*
3 (21.43) 11 (78.57) Reference
Group A statins only prescribed before and during first
trimester, n = 64*
3 (4.69) 61 (95.31) 0.18 0.03, 1.01 0.05
Group C statins only prescribed between 1 year before and
1 month before pregnancy, n = 67*†
7 (10.45) 60 (89.55) 0.43 0.10, 1.91 0.27
Maternal age at end of pregnancy, years
1 8 0( 0 ) 2( 1 . 5 2 ) <0.001 – 0.99
19–25 4 (30.77) 18 (13.64) 5.63 1.16, 27.40 0.03
26–34 3 (23.08) 76 (57.58) Reference
35 6 (46.15) 36 (27.27) 4.22 1.00, 17.85 0.05
Socioeconomic information (at end of pregnancy)
Urban dweller (y/n) 12 (92.31) 96 (72.73) 4.50 0.56, 35.86 0.15
Welfare beneficiary (y/n) 6 (46.15) 51 (38.64) 1.36 0.43, 4.28 0.60
Living alone (y/n) 6 (46.15) 28 (21.21) 3.18 0.99, 10.23 0.05
Education
Secondary education incomplete (<11 years) 4 (30.77) 43 (32.58) Reference
Secondary education completed 5 (38.46) 27 (20.45) 1.99 0.49, 8.07 0.33
Post secondary education (12–15 years) 4 (30.77) 53 (40.15) 0.81 0.19, 3.43 0.78
University education 0 (0.00) 9 (6.82) <0.001 – 0.98
Maternal co-morbidities
Diabetes status‡ (y/n) 7 (53.85) 28 (21.21) 4.33 1.35, 13.93 0.01
Chronic or gestational hypertension or prescription for 5 (38.46) 28 (21.21) 2.32 0.70, 7.65 0.17
antihypertensives§ (y/n)
Hypothyroidism before or during pregnancy¶ (y/n) 3 (23.08) 12 (9.09) 3.00 0.72, 12.41 0.13
Different medications > 2 (excluding antilipaemic drugs) 7 (53.85) 62 (46.97) 1.32 0.42, 4.13 0.64
during pregnancy
Health services utilization
Prenatal visits 7 5 (38.46) 36 (27.27) 1.67 0.51, 5.43 0.40
Medical visits 3 in year prior to pregnancy 10 (76.92) 115 (87.12) 0.49 0.12, 1.97 0.32
Different prescribers 2 in year prior to and during 13 (100.00) 114 (86.36) <0.001 – 0.97
pregnancy
ED visit or hospitalization in year prior to and during 9 (69.23) 107 (81.06) 0.53 0.15, 1.84 0.31
pregnancy (y/n)
Visit to an OB/GYN during pregnancy (y/n) 12 (92.31) 107 (81.06) 2.80 0.35, 22.55 0.33
Pregnancy in previous year (y/n) 2 (15.38) 14 (10.61) 1.53 0.31, 7.63 0.60
Gestational age at delivery <37 weeks 6 (46.15) 11 (8.33) 9.43 2.69, 33.01 <0.001
Birth weight <2500 g 3 (23.08) 13 (9.85) 2.75 0.67, 11.27 0.16
Gender of baby, male 6 (46.15) 70 (53.03) 0.76 0.24, 2.38 0.64
OR, odds ratio; 95% CI, 95% Confidence Interval. *Women with live births and complete mother–baby linkage data. †Includes
one woman with a twin birth. ED, Emergency department; OB/GYN, obstetrician and gynaecologist; y/n, yes/no. ‡Diabetes status
defined as a diagnosis of chronic diabetes in the year before pregnancy (ICD-9; 250.0–250.9, 271.4, 790.2) or gestational
diabetes diagnosed at 26 weeks of pregnancy (ICD-9; 648.0, 648.8), or filled prescriptions for medications for diabetes in the
12 months before and during pregnancy. §Chronic hypertension defined as diagnosis of hypertension in year before pregnancy
(ICD-9; 401.0–405.9, 362.1, 416.0, 437.2, 796.2) or filled prescriptions for any antihypertensive drugs under the American
Hospital Formulary Service (AHFS) class 24 : 08. Gestational hypertension defined as a diagnosis made at 20 weeks of
pregnancy (ICD-9; 642.0–642.9). ¶Hypothyroidism defined as; ICD-9; 244.0 or the use of thyroid medication (AHFS 68:36.04)
at any time before or during pregnancy.
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Characteristics of cases and controls in two study groups and risk of congenital anomalies in relation to characteristics
Group A
n = 64
Group C
(ref. group), n = 67
Crude
OR 95% CI P-value
Cases,
n (%)
Controls,
n (%)
Cases,
n (%)
Controls,
n (%)
Risk of congenital anomalies in Group A 3 (4.69) 61 (95.31) 7 (10.45) 60 (89.55) 0.42 0.10, 1.71 0.23
Maternal age at end of pregnancy, years
1 8 0( 0 ) 0( 0 ) 0( 0 ) 1( 1 . 6 7 ) <0.001 – 0.99
19–25 2 (66.67) 6 (9.84) 1 (14.29) 11 (18.33) 4.18 0.77, 22.53 0.10
26–34 0 (0) 35 (57.38) 3 (42.86) 36 (60.00) Reference
35 1 (33.33) 20 (32.79) 3 (42.86) 12 (20.00) 2.96 0.62, 13.99 0.17
Socioeconomic information (at end of pregnancy)
Urban dweller (y/n) 3 (100.00) 44 (72.13) 6 (85.71) 43 (71.67) 3.52 0.43, 28.83 0.24
Welfare beneficiary (y/n) 2 (66.67) 20 (32.79) 2 (28.57) 26 (43.33) 1.09 0.29, 4.06 0.90
Living alone (y/n) 2 (66.67) 8 (13.11) 2 (28.57) 17 (28.33) 2.56 0.67, 9.77 0.17
Education
Secondary education
incomplete (<11 years)
2 (66.67) 22 (36.07) 2 (28.57) 17 (28.33) Reference
Secondary education completed 0 (0) 14 (22.95) 3 (42.86) 10 (16.67) 1.22 0.25, 5.92 0.81
Post secondary education (12–15 years) 1 (33.33) 22 (36.07) 2 (28.57) 27 (45.00) 0.60 0.13, 2.83 0.51
University education 0 (0) 3 (4.92) 0 (0) 6 (10.00) <0.001 – 0.97
Maternal co-morbidities
Diabetes status* (y/n) 1 (33.33) 12 (19.67) 3 (42.86) 10 (16.67) 3.00 0.78, 11.54 0.11
Chronic or gestational hypertension or
prescription for antihypertensives†
(y/n)
0 (0) 15 (24.59) 3 (42.86) 8 (13.33) 1.83 0.44, 7.61 0.41
Hypothyroidism before or during
pregnancy‡ (y/n)
1 (33.33) 7 (11.48) 1 (14.29) 4 (6.67) 2.50 0.47, 13.27 0.28
Different medications > 2 (excluding
antilipaemic drugs) during pregnancy
2 (66.67) 31 (50.82) 2 (28.57) 25 (41.67) 0.77 0.21, 2.88 0.70
Health services utilization
Prenatal visits  7 1 (33.33) 15 (24.59) 2 (28.57) 17 (28.33) 1.19 0.29, 4.89 0.81
Medical visits  3 in year prior to
pregnancy
2 (66.67) 54 (88.52) 5 (71.43) 53 (88.33) 0.30 0.07, 1.32 0.11
Different prescribers  2i ny e a rp r i o rt o
and during pregnancy
3 (100.00) 52 (85.25) 7 (100.00) 51 (85.00) – – 0.96
ED visit or hospitalization in year prior to
and during pregnancy (y/n)
3 (100.00) 48 (78.69) 4 (57.14) 50 (83.33) 0.55 0.13, 2.28 0.41
Visit to an OB/GYN during
pregnancy (y/n)
3 (100.00) 51 (83.61) 6 (85.71) 48 (80.00) 2.00 0.24, 16.61 0.52
Pregnancy in previous year (y/n) 0 (0) 6 (9.84) 1 (14.29) 7 (11.67) 0.92 0.11, 7.88 0.94
Gestational age at delivery < 37 weeks 1 (33.33) 5 (8.20) 3 (42.86) 5 (8.33) 7.40 1.79, 30.65 0.01
Birth weight < 2500 g 1 (33.33) 7 (11.48) 1 (14.29) 5 (8.33) 2.271 0.43, 11.95 0.33
Gender of baby, male 1 (33.33) 33 (54.10) 3 (42.86) 32 (53.33) 0.574 0.15, 2.14 0.41
OR, odds ratio; 95% CI, 95% Confidence Interval. ED, Emergency department; OB/GYN, obstetrician and gynaecologist; y/n,
yes/no. *Diabetes status defined as a diagnosis of chronic diabetes in the year before pregnancy (ICD-9; 250.0–250.9, 271.4,
790.2) or gestational diabetes diagnosed at 26 weeks of pregnancy (ICD-9; 648.0, 648.8), or filled prescriptions for
medications for diabetes in the 12 months before and during pregnancy. †Chronic hypertension defined as diagnosis of
hypertension in year before pregnancy (ICD-9; 401.0–405.9, 362.1, 416.0, 437.2, 796.2) or filled prescriptions for any
antihypertensive drugs under the American Hospital Formulary Service (AHFS) class 24 : 08. Gestational hypertension defined as
a diagnosis made at 20 weeks of pregnancy (ICD-9; 642.0–642.9). ‡Hypothyroidism defined as ICD-9; 244.0 or the use of
thyroid medication (AHFS 68 : 36.04) at any time before or during pregnancy.
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504 64:4 Br J Clin PharmacolA was 0.36 (95% CI 0.06, 2.18), when compared with
group C.
There was no evidence of a nonlinear trend with the
quadratic term for maternal age entered into the model
(P for the quadratic term in the ﬁrst multivariate analy-
sis = 0.22; P for the quadratic term in second multivari-
ate analysis = 0.50). Under the alternative assumptions
for missing data, i.e. living alone by default and educa-
tion 10 years, the point estimates for groupsAand C in
the ﬁrst multivariate analysis of the entire study cohort
stratiﬁed by study group were adjusted OR = 0.72 (0.10,
5.31) and adjusted OR = 1.51 (0.25, 9.26), respectively.
If 16 years of education was assumed, then the
adjusted OR estimates were 0.73 (95% CI 0.10, 5.48)
and 1.54 (95% CI 0.24, 9.79) for groupsAand C, respec-
tively. The adjusted ORs in the second multivariate
analysis (comparing groupAwith C) under these various
assumptions remained unchanged.
The most common anomalies detected were related to
anomalies of the heart (ICD-9 745, 746) (Table 5). In
group A, the three anomalies detected were an unspeci-
ﬁed anomaly of the heart, a ventricular septal defect and
an atrial septal defect. The statin medications prescribed
in these three cases were lovastatin, atorvastatin and
simvastatin. Despite the prevalence in use of pravastatin
(20%) during the ﬁrst trimester, there were no congenital
anomalies associated with this medication among the
live births. A variety of unrelated anomalies were repre-
sented in group B: one cardiac anomaly, one musculosk-
eletal anomaly and one case of tuberous sclerosis, and an
anomaly of the eye. Similarly, a variety of unrelated
anomalies was represented in group C, including mus-
culoskeletal, limb, cardiac and respiratory anomalies,
suggesting no speciﬁc pattern in congenital anomalies.
In all three groups, the dose of medications being taken
was the standard recommended therapeutic dose [27].
Discussion
In this study, we found that the overall incidence of
congenital anomalies in pregnancies where prescriptions
for statins had been ﬁlled in the ﬁrst trimester of preg-
nancy (3/64, 4.69%) was not statistically greater than the
incidence in those pregnancies where prescriptions for
ﬁbrates only had been ﬁlled in the ﬁrst trimester (3/14,
21.43%), or where the statins had been stopped at least
1 month before conception (7/67, 10.45%). There was
no evident pattern in the types of congenital anomalies
among the live births. However, the sample size of our
study was small and lacked sufﬁcient power to detect
small increases in overall risk among those taking statins
during pregnancy. Furthermore, the number of cases
ascertained was also very small. We acknowledge that
this is a limitation in drawing inferences from the statis-
tical tests of signiﬁcance. Nevertheless, this is an issue
common to many such studies published so far.
The congenital anomalies detected in the three cases
where statin prescriptions had been ﬁlled in the ﬁrst
trimester involved lovastatin, simvastatin and atorvasta-
tin. No malformations were detected among the 11
infants exposed to pravastatin. One prevailing theory is
that statins with high afﬁnity for lipid environments
(including, simvastatin > lovastatin > atorvastain > ceri-
vastatin > ﬂuvastatin) more readily enter extrahepatic
tissues,includingtheembryoduringpregnancy,andthus
have a greater potential to downregulate cholesterol bio-
synthesis [11]. In case reports of statin-exposed pregnan-
cies and outcomes [11], all cases of adverse outcomes
at birth were associated with lipophilic statins; no mal-
formations were reported among infants exposed to
pravastatin.
Studies on humans to date have not shown statins to
be potent teratogens or to cause particular patterns of
congenital anomalies. In our study, the 3/64 cases of live
babies with congenital anomalies associated with ﬁlling
prescriptions for statins in the ﬁrst trimester of preg-
nancy consisted of an unspeciﬁed anomaly of the heart,
a ventricular septal defect and an atrial septal defect.
Similarly, another study [11] involving the evaluation of
reports on ﬁrst-trimester statin exposures from the
FDA’s Medical Products Reporting Program reported
18 live births with structural anomalies. Detected
anomalies included: limb deﬁciencies (n = 2), cleft
palate (n = 1), cleft lip (n = 2), oesophageal atresia
(n = 1), spina biﬁda (n = 1), duodenal atresia (n = 1),
polydactyly (n = 1), hypospadias (n = 1), constriction of
pyelourethral junction (n = 1), clubbed foot (1), verte-
bral, anal, tracheo-oesophageal, renal (VATER) (n = 1),
aqueductal stenosis (n = 1), ‘severe deformity’ (n = 1),
microtia (n = 1), ‘cardiovascular defect’ (n = 1) and
an atrial/ventricular septal defect/aortic hypoplasia (as
subsequently corrected [12]). The statins implicated
were atorvastatin, simvastatin and lovastatin.
Most studies of associations of human birth defects,
such as ours, are undertaken in live births. However, live
births represent only part of the population in which
such adverse outcomes may be detected [28]. Although
the proportion of those congenital anomalies that can be
attributed to medication exposure is low compared with
other environmental causes [29], it is still feasible that
some anomalies not captured by our analysis, which
considered only live births, could also have been asso-
ciated with medication use. For example, if the number
of cases in the pregnancies lost to ascertainment from
our study group A exceeded the number of observed
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Description of congenital anomalies in study groups
Congenital anomalies by study group
Antilipaemic
drug
Daily
dose
(mg)
Maternal
age at
end of
pregnancy
(years)
Diabetes
status*
(y/n)
Gestational
age at
delivery
(weeks)
Gender
of baby
(f/m)
ID A. Statins only prescription, before and
during first trimester, n = 3
1 Unspecified anomaly of the heart (ICD-9;
746.9)
Lovastatin† 20 35 n 34 f
2 Ventricular septal defect (ICD-9; 745.4) Simvastatin† 10 24 n 41 f
2 Unspecified defect of septal closure (ICD-9;
745.9)
Simvastatin† 10
3 Other specified anomaly of heart (ICD-9;
746.8)
Atorvastatin† 10 21 y 37 m
3 Ostium secundum type atrial septal defect
(ICD-9: 745.5)
Atorvastatin† 10
ID B. Fibrates or nicotinic acid only
prescription, before and during first
trimester, n = 3
4 Transposition of great vessels (ICD-9;
745.1)
Fenofibrate† 200 41 y 36 m
4 Unspecified anomaly of heart (ICD-9;
746.9)
Fenofibrate† 200
4 Congenital anomaly unspecified (ICD-9;
759.9)
Fenofibrate† 200
5 Unspecified anomaly of musculoskeletal
system (ICD-9; 756.9)
Fenofibrate† 200 37 y 40 m
6 Tuberous sclerosis (ICD-9; 759.5) Fenofibrate† 200 20 y 34 f
6 Unspecified anomaly of eye (ICD-9; 743.9) Fenofibrate† 200
ID C. Statins only prescription, between 1 year
before and 1 month before pregnancy,
n = 7
7 Unspecified anomaly of musculoskeletal
system (ICD-9: 756.9)
Simvastatin‡ 10 23 n 40 f
8 Unspecified anomaly of unspecified limb
(ICD-9: 755.9)
Atorvastatin‡ 10 30 y 36 m
9 Ventricular septal defect (ICD-9: 745.4) Atorvastatin‡ 10 37 y 38 f
10 Ostium secundum type atrial septal defect
(ICD-9: 745.5)
Simvastatin‡ 20 37 y 30 m
11 Unspecified anomaly of respiratory system
(ICD-9: 748.9)
Lovastatin‡ 20 27 n 36 m
12 Ventricular septal defect (ICD-9: 745.4) Atorvastatin‡ 10 37 n 37 f
13 Varus deformities of feet (ICD-9: 754.5) Atorvastatin‡ 40 26 n 41 f
*Diabetes status defined as a diagnosis of chronic diabetes in the year before pregnancy (ICD-9; 250.0–250.9, 271.4, 790.2)
or gestational diabetes diagnosed at 26 weeks of pregnancy (ICD-9; 648.0, 648.8), or the filling of prescriptions for
medications for diabetes in the 12 months before and during pregnancy. †Represent prescriptions for antilipaemic medications
filled during the first trimester (some women may also have filled prescriptions before the first trimester but the duration of
treatment overlapped into the first trimester). ‡Represent prescriptions for antilipaemic medications lasting up to 1 month before
pregnancy. Subjects in this group did not fill prescriptions for antilipaemic medications during pregnancy. Tuberous sclerosis:
familial neurocutaneous disease characterized by epilepsy, mental deterioration, adenoma sebaceum, nodules and sclerotic
patches on the cerebral cortex, retinal tumours, tumours of the heart or kidneys.
B. Ofori et al.
506 64:4 Br J Clin Pharmacolcases, the opposite results to what we reported could
have been produced. This is an important limitation, but
a problem common to many studies of the associations
of birth defects in humans. Under these circumstances
the possibility exists for the Yule–Simpson effect (Sim-
pson’s paradox) [30], a statistical paradox in which an
effect in two groups measured separately (such as con-
genital anomalies among nonlive births and among live
births) is reversed when the groups are combined. This
effect has been examined quantitatively [28], illustrated
by considering maternal female sex hormone exposure
and congenital cardiovascular defects. Clearly, congeni-
tal anomalies in nonlive births could have an important
impact on OR estimates.
To our knowledge, there is no extensive evidence sug-
gesting that the indication for antilipaemic treatment
could itself be a cause of adverse fetal outcome other
than a case report of possible intrauterine growth restric-
tion [8]. However, common co-morbidities associated
with the use of antilipaemic medications such as hyper-
tension, hypothyroidism and diabetes could increase the
risk of adverse fetal outcome. Diabetes, for example, is
known to be strongly associated with major congenital
anomalies and perinatal mortality [31–33] and is an
aetiological factor for abortion [29]. In this study, care
was taken to select groups of women that were compa-
rable to account for any possible effects of indication;
two comparator groups were selected, with both groups
consisting of women who had previously had or cur-
rently had an indication for antilipaemic medication
treatment.
In this database study we were able to assemble a
cohort of all women known to have been prescribed
statins or ﬁbrates within a population, and ascertain
pregnancy status. This method allowed us to ascertain a
denominator (a deﬁned population of exposed individu-
als) from which the cases (the numerator) are drawn.
Controlled epidemiological studies are considered to be
more appropriate than uncontrolled case reports in
establishing a relationship between gestational drug
exposure and pregnancy outcomes in humans [11].
Nevertheless, there is a need for caution in trying to
identify patterns, particularly those concerning anoma-
lies that are relatively common, when study populations
are small.
Pharmacoepidemiolgical studies based on administra-
tive databases are important and may yield valuable
information despite limitations of the incompleteness of
information on potential confounders or on certain clini-
cal variables of interest. In this study, we did not have
access to information such as the reasons for the termi-
nation of a pregnancy. Information on other potential
confounding variables such as smoking and folic acid
intake were not available. We also acknowledge that an
assumption of our study was that those who ﬁlled a
prescription were also sufﬁciently exposed to the medi-
cines, but absolute noncompliance with medications
obtained by pregnant women is known to be low, at
about 8% [34].
An advantage of database studies that include the
routine collection of information on dispensed drugs,
including name, dose and amount dispensed, is the
avoidance of limitations associated with the need for
long-term recall by study subjects (that may result in
recall bias). They allow the rapid assembly of cohorts
that would otherwise be costly and time consuming if
done prospectively. Such database research provides
valuable information in the investigation of associations
that might have an important public health impact.
The prevention of severe hypercholesterolaemia
during pregnancy remains desirable. However, for the
majority of women discontinuation of antilipaemic
drugs such as statins should have little impact on them or
their babies. Given the continuing uncertainty over the
safety of statins for the fetus, the avoidance of their use
during pregnancy remains the best advice; consequently,
women on statins should plan their pregnancies to guar-
antee the best outcome.
In conclusion, we did not detect a pattern in congeni-
tal anomalies or ﬁnd evidence of an increased risk of
fetal congenital anomalies in the live-born infants of
women ﬁlling prescriptions for statins in the ﬁrst trimes-
ter of pregnancy, compared with women on ﬁbrates or
those who stopped statins before pregnancy. However,
studies of larger populations that include more informa-
tion on nonlive births are necessary before conﬁrming
or refuting an association between statins and fetal
congenital anomalies.
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